

Table S1. Survival time in the low and high expression groups of histone markers.

Group	Mean \pm standard error of the mean	95% confidence interval	P-value	χ^2
Low H3K9me2	42.521 \pm 2.195	38.219-46.823	0.028 ^a	4.802
High H3K9me2	34.061 \pm 3.861	26.493-41.629		
Low EHMT2	41.761 \pm 2.399	37.059-46.463	0.030 ^a	4.736
High EHMT2	32.243 \pm 3.364	25.650-38.837		
Low expression of both markers group	46.000 \pm 2.711	40.686-51.314	0.036 ^a	6.623
High expression of both markers group	31.467 \pm 5.671	20.352-42.582		
Other groups	37.943 \pm 2.830	32.396-43.491		

^aP<0.05. H3K9me2, di-methylated lysine 9 of histone H3; EHMT2, euchromatic histone lysine methyltransferase 2.

Table SII. Univariate Kaplan-Meier survival analysis between clinicopathologic variables and histone marks in the patients with gastric cancer.

Characteristics	Percentage (%)	χ^2	P-value
Sex			
Male	36.59	0.005	0.943
Female	36.11		
Age (years)			
≤60	35.59	0.234	0.629
>60	37.29		
Differentiation degree			
Well + moderately differentiated	58.93	23.920	<0.001 ^b
Poorly differentiated	16.13		
Lymph node metastasis			
Negative	70.59	60.853	<0.001 ^b
Positive	10.45		
Distal metastasis			
Negative	39.09	60.853	<0.001 ^b
Positive	0.00		
pTNM			
I+II	65.08	96.266	<0.001 ^b
III+IV	3.64		
H3K9me2			
Low	39.51	4.802	0.028 ^a
High	29.73		
EHMT2			
Low	37.84	4.736	0.030 ^a
High	34.09		

^aP<0.05, ^bP<0.001. H3K9me2, di-methylated lysine 9 of histone H3; EHMT2, euchromatic histone lysine methyltransferase 2.